Clinical Efficacy of Amoxicillin versus Cefodoxime Proxetil for the Treatment of Pneumonia

Sajani Islam¹, Bithi Debnath², Md. Azizul Hoque³

¹Junior Consultant (Pediatrics), Upazila Health Complex, Dohar, Dhaka, Bangladesh; ²Assistant Professor, Department of Pediatric Neurology, National Institute of Neurosciences and Hospital, Dhaka, Bangladesh; ³Professor & Former Head, Department of Pediatrics, Mymensingh Medical College Hospital, Mymensingh, Bangladesh

[Received: 7 March 2019; Accepted: 20 May 2019; Published: 1 June 2019]

Abstract

Background: Pneumonia is one of the leading cause of death of under 5 children in Bangladesh. WHO recommended Amoxicillin and Co-trimoxazole as first line drugs for the treatment of pneumonia. But emergence of antimicrobial resistance against the common pathogens prompted WHO panel to find out evidence based recommendations for treating pneumonia. Objectives: The purpose of the present study was to compare the effect of oral Amoxicillin and Cefpodoxime proxetil in children with pneumonia. Methodology: This prospective randomized study was conducted in outpatient department of Pediatrics at Mymensingh Medical College Hospital, Mymensingh, Bangladesh from March 2010 to March 2012 for a period of two (02) years. Baseline data were collected from 197 patients, thereafter 85 patients from Amoxicillin group and 89 patients from Cefpodoxime proxetil group completed the trial. Results: Among the enrolled (197) children, majority (53%) were boys. The baseline clinical characteristics before therapy were not significantly different in both the Amoxicillin and Cefpodoxime proxetil groups. Changes in duration of cough, duration of dyspnea, duration of fast breathing, mean heart rate, temperature and respiratory rate were observed. After treatment with Amoxicillin and Cefpodoxime proxetil similar significant improvement in mean body temperature, respiratory rate and wheeze were observed which were almost similar in both the groups (p <0.001). While comparing the efficacy, treatment outcome did not differ significantly in both the groups (p >0.127). Chi-square test revealed no statistically significant difference between patients treated with Amoxicillin and those treated with Cefpodoxime proxetil (p =0.171). Conclusion: Response to therapy in both Amoxicillin and Cefpodoxime Proxetil groups was nearly similar and the difference was statistically insignificant. [Bangladesh Journal of Infectious Diseases, June 2019;6(1):22-25]

Keywords: Pneumonia; Amoxicillin; Cefpodoxime Proxetil; Bangladesh; antibiotic resistant
Introduction

Acute lower respiratory tract infections especially pneumonia is a global burden. It is the leading killer of children and causes 19% of total under-five deaths in the world. Pneumonia constitutes 21.0% deaths occurring in the developing countries, mostly in the South West Asia. In Bangladesh, incidence of pneumonia is very high that accounts up to 18.0% deaths of this age group. Specific WHO antimicrobial drugs recommendations for the treatment of pneumonia are based on data that Streptococcus pneumonia and Haemophilus influenza are the most common causes of bacteria in these countries. Based on these findings, amoxicillin and cotrimoxazole are recommended for the treatment of pneumonia at primary level of health care facilities.

Although Co-trimoxazole and Amoxicillin are the WHO recommended drugs for pneumonia, high resistance of the pathogens is observed in different studies (Co-trimoxazole 75.0% and Amoxicillin 32.0 to 35.0%)\(^4\).\(^5\). Streptococcus pneumoniae and Haemophilus influenza also exhibit high resistance against macrolides\(^6\).\(^10\). Thus, for rising resistance of these two common bacteria against these drugs, it is necessary to find an alternative antibiotic for the treatment of pneumonia, such as the third generation cephalosporin.

Cefpodoxime was in fact the most active among oral antibiotic agents tested and covered all major respiratory tract pathogens circulating in the three European countries like Spain, Italy and Austria surveyed. Taking into account its favourable pharmacokinetic parameters and tolerability, Cefpodoxime represents an appropriate choice in the empirical treatment of community acquired respiratory tract infections\(^11\).\(^12\). Considering all these, this study was conducted to observe the clinical efficacy of Cefpodoxime proxitel and Amoxicillin in treatment of pneumonia.

Methodology

This was an open label randomized controlled trial study conducted in outpatient Department of Paediatrics of Mymensingh Medical College Hospital, Mymensingh, Bangladesh from March 2010 to March 2012 for a period of two years and one month. Patients who met the inclusion criteria were enrolled in this study. Pneumonia was diagnosed according to WHO criteria. Children having chronic disease, recurrent wheeze, who already started antibiotics and failed to follow up were excluded from the study. Written informed consent was taken from each parent and a randomization scheme was developed after parents chose to have the preferred drug willingly. Then they were divided into two groups of which one group was treated with oral amoxicillin and other group was treated with oral cefpodoxime proxitel.

Amoxicillin was given three times daily (30mg/kg/day) and cefpodoxime proxitel was given twice daily (10mg/kg/day) for five days. Follow up was done on 3\(^{rd}\) and 5\(^{th}\) day after starting treatment. Patients were declared as cured when the sign-symptoms of pneumonia were completely disappeared. The patients who did not cure were needed hospitalization and change in prescribed antibiotics. Data were collected in a preformed questionnaire and statistical analysis was performed by using SPSS version 12.

Result

Among 197 enrolled patients 23 respondents could not complete the trial. Finally 85 patients from Amoxicillin group and 89 patients from Cefpodoxime Proxetil group were analyzed.

Table 1: Baseline Characteristics of Study Population

| Variables                  | Group A       | Group B       |
|----------------------------|---------------|---------------|
| Mean age(month ±SD)        | 20.16±15.79   | 15.75±7.87   |
| Gender                     |               |               |
| • Male                     | 53(54.1%)     | 52(52.5%)     |
| • Female                   | 45(45.9%)     | 47(47.5%)     |
| Monthly Income             |               |               |
| • <5000                    | 18(18.4%)     | 17(17.2%)     |
| • 5000-10000               | 41(41.8%)     | 44(44.4%)     |
| • >10000                   | 39(39.8%)     | 38(38.4%)     |
| Person living in one room  |               |               |
| • ≤2                       | 5(5.1%)       | 7(7.1%)       |
| • 3                        | 21(21.4%)     | 19(19.2%)     |
| • ≥4                       | 72(73.5%)     | 73(73.7%)     |
| Smoking in family          |               |               |
| • Yes                      | 41(41.8%)     | 33(33.3%)     |
| • No                       | 57(58.2%)     | 66(66.7%)     |

Group A= Amoxicillin group; Group B= Cefpodoxime Proxetil group

Among the enrolled children, the mean age of amoxicillin group was 20.16 months and that for cefpodoxime proxetil was 15.75 months. There were no significant difference regarding the baseline characteristics of patient (Table 1).
Table 2: Baseline clinical features before therapy

| Variables                              | Group A          | Group B          | P value |
|----------------------------------------|------------------|------------------|---------|
| Duration of cough (Day) (Mean±SD)      | 6.89±3.48        | 4.59±0.639       | 0.57    |
| Duration of difficult breathing (Day)  | 1.83±0.38        | 1.82±0.388       | 0.82    |
| Duration of fast breathing (Day)       | 2.11±0.32        | 2.01±0.101       | 0.70    |
| Heart rate/min (Mean±SD)               | 109.1±13.81      | 103.3±3.69       | 0.68    |

Baseline clinical features before therapy were also statistically insignificant (Table 2).

Table 3: Response to therapy with Amoxicillin (n=85)

| Variables                              | Before Treatment | After Treatment | 95% CI      | P value |
|----------------------------------------|------------------|----------------|-------------|---------|
| Body Temperature (Mean±SD)             | 100.47±1.24      | 99.35±1.97     | 0.781 to 1.463 | <0.001 |
| Respiratory rate (Mean±SD)             | 47.39±9.05       | 44.22±9.51     | 1.637 to 4.692 | <0.001 |
| Added sound n(%)                       | 28(32.9)         | 01(1.18)       |             | <0.001 |

Table 4: Response to therapy with Cefpodoxime Proxetil (n=89)

| Variables                              | Before Treatment | After Treatment | 95% CI      | P value |
|----------------------------------------|------------------|----------------|-------------|---------|
| Body Temperature (Mean±SD)             | 99.29 ± 1.63     | 98.78±1.65     | 0.197 to 0.805 | 0.002  |
| Respiratory rate (Mean±SD)             | 49.08±3.77       | 44.809±7.79    | 2.946 to 5.616 | <0.001 |
| Added sound, n(%)                      | 35(39.3)         | 00             |             | <0.001 |

Table 5: Comparison of response to therapy in both groups

| Variables                              | Group A          | Group B          | 95% CI       | P value |
|----------------------------------------|------------------|------------------|--------------|---------|
| Body Temperature (Mean±SD)             | 99.35±1.97       | 98.78±1.65       | -3.17 to 2.02 | 0.44    |
| Respiratory rate (Mean±SD)             | 44.22±9.51       | 44.80±7.79       | 0.015 to 1.11 | 0.66    |
| Added sound, n(%)                      | 01(1.18)         | 00               |              | 0.127   |

Table 6: Comparison of treatment outcome in both groups

| Variables | Group A          | Group B          | P value |
|-----------|------------------|------------------|---------|
| Cured     | 68(80%)          | 77(86.5%)        | 0.171   |
| Not cured | 17(20%)          | 12(13.5%)        |         |
| Total     | 85(100.0%)       | 89(100.0%)       |         |

After treatment with the Amoxicillin and Cefpodoxime Proxetil group, significant improvement (p<0.001) in mean body temperature, respiratory rate and added sound were observed in both groups which were almost similar.

When we compared the response to therapy (Table 5) and treatment outcome (Table 6) among Amoxicillin and Cefpodoxime Proxetil group, it was found insignificant association.
Discussion

This open label randomized controlled trial was designed to compare the effect of oral Amoxicillin and cefpodoxime proxetil in children with pneumonia. Among the total enrolled children majority were boys. Age and sex distribution of this study found similarity with a study conducted by Jones. The baseline clinical features before therapy were not significantly different in both the amoxicillin and cefpodoxime proxetil group. Changes in duration of cough, duration of difficult breathing, duration of fast breathing, mean heart rate, mean temperature and mean respiratory rate were observed. After treatment with the amoxicillin and cefpodoxime proxetil, significant improvement in mean body temperature, respiratory rate and added sound were observed which were almost similar in both groups (p<0.001). WHO assemble an international panel to review the literature on childhood pneumonia and to develop evidence based recommendations for the empirical treatment of non-severe pneumonia among children managed by first-level health providers. Treatment should target the bacterial causes most likely that lead to severe disease, including Streptococcus pneumoniae and Haemophilus influenzae and the best first-line agent is Amoxicillin, given thrice daily for 5 days.

In an international experience among 7351 patients, cefpodoxime proxetil has proven efficacious and well tolerated, and therefore should be added to antibacterial armamentarium for use in community-acquired infections and in hospitals for follow-up treatment after initial parenteral therapy. Based on these characteristics, cefpodoxime proxetil is a suitable option for the treatment of paediatric patients with various common bacterial infections. While comparing the efficacy of both the drugs, there was no such study found to compare in this era. In this trial, the treatment outcome in both groups showed that patients treating with amoxicillin and cefpodoxime proxetil cured more than two thirds of the patients. There was no statistically significant difference between patients treated with amoxicillin and those treated with cefpodoxime proxetil.

Conclusion

The baseline clinical characteristics before therapy are nearly same in both the groups. After treatment with amoxicillin and cefpodoxime proxetil, significant improvement in both the groups are observed. The response to therapy in both the groups are almost similar and the difference is statistically insignificant. Cefpodoxime proxetil is not found to have a superior efficacy than amoxicillin. Amoxicillin can still be used for community based treatment of pneumonia as it is cheaper and not resistant to common bacteria. Furthermore it can be used in all health care level as it is supplied by the government. Further study with large sample size should be conducted to validate the efficacy.

References

1. Cause-specific mortality estimates from: World Health Organization, World Health Report 2005: Make Every Mother and Child Count, World Health Organization, Geneva, under-five mortality estimates from: UNICEF, The State of the World’s Children 2006, New York, 2005.
2. World Health Organization, International Statistical Classification of Diseases and Related Health Problems, Tenth Revision, World Health Organization, Geneva, 2006.
3. World Health Organization, Technical basis for the WHO recommendation on the management of pneumonia in children at first-level facilities. WHO/ARI/91.20. Geneva:WHO, 1991.
4. ISCAP Study Group. BMJ 2004;328:791.
5. Saha SK. Surveillance of pneumococcus. Health & Sciences Bull.2007.
6. Perez-Trallero E, Fernandez-Mazarra C, Garcia-Rey C, Bouza E, Aguilar L, Garcia-de-Lomas J et al. Antimicrobial susceptibilities of 1684 Streptococcus pneumoniae and 2039 Streptococcus pyogenes and their ecological relationships: results of a 1-year(1998-1999) multicenter surveillance in spain. Antimicrobial Agents and Chemotherapy 2001;45:3334-40.
7. Marchese A, Tonoli E, Debbia EA, Schito GC. Macrolide mechanisms and expression of phenotypes among Streptococcus pneumoniae circulating in Italy. Journal of Antimicrobial Chemotherapy 1999;44:461-4.
8. Kelly MA, Weber DJ, Gillian P, Cohen MS. Breakthrough pneumococcal bacteremia in patients being treated with azithromycin and clarithromycin. Clinical Infectious Diseases 2000;31:1008-11.
9. Fogarty C, Goldschmidt R, Bush K. Bacteremic pneumonia due to multidrug-resistant pneumococci in 3 patients treated unsuccessfully with levofloxacin. Clinical Infectious Diseases 2000;31:613-5.
10. Carbon C, Poole MD. The role of newer macrolides in the treatment of community-acquired respiratory tract infection. A review of experimental and clinical data. Journal of Chemotherapy 1999;11:107-18.
11. Geddes AM. Cefpodoxime proxetil in the treatment of lower respiratory tract infections. Drugs 1991;42:Suppl.3:34-40.
12. Gian CS, Apostolos G, Jose P. Antibacterial activity of oral antibiotics against community acquired respiratory pathogens from three European countries. Journal of Antimicrobial Chemotherapy 2002;50:Topic T1.7-11.
13. Jones G. How many child deaths can we prevent this year? The Lancet 2003;362:65-71.
14. Grant GB, Campbell H, Dowell SF, Graham SM, Klugman KP, Mulholland JK. Recommendations for treatment of childhood non-severe pneumonia. Lancet 2009;9(3):185-96.
15. Klein M. Multicenter trial of cefpodoxime proxetil vs. Amoxicillin-clavulanate in acute lower respiratory tract infections in childhood. International Study Group. Pediatr Infect Dis J 1995;14(4 Suppl):S19-22.
16. Futon B, Perry CM. Cefpodoxime proxetil: A review of its use in the management of bacterial infections in pediatric patients. Pediatric Drugs 2001;3(2):137-158(22).